تخطى إلى المحتوى / Skip to content
Clinical Reference Hub

Acute Respiratory Failure

Inability of the respiratory system to maintain adequate gas exchange.

Medical disclaimer: This page is an educational clinical-decision-support reference for licensed healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. If you are a patient with symptoms, consult a qualified physician. Always verify dosing and guidance against current clinical guidelines and the cited references.

🩺What is Acute Respiratory Failure?

The CURB-65 score was developed by Lim et al. as part of the British Thoracic Society (BTS) collaborative study, published in Thorax in 2003. It was designed as a simplified and validated severity assessment tool for community-acquired pneumonia (CAP) that could be readily calculated at the bedside. The score is derived from the earlier CURB score and incorporates five binary variables, each contributing 1 point: new-onset confusion (C), blood urea nitrogen greater than 19 mg/dL or urea greater than 7 mmol/L (U), respiratory rate of 30 breaths per minute or greater (R), systolic blood pressure below 90 mmHg or diastolic blood pressure 60 mmHg or less (B), and age 65 years or older (65). The total score ranges from 0 to 5, and the score correlates with 30-day mortality in a stepwise fashion. The validation cohort included over 80,000 patients across multiple countries. The CURB-65 score is recommended by the British Thoracic Society and the National Institute for Health and Care Excellence (NICE) for severity assessment in CAP. A related score called CRB-65 excludes the urea measurement and is appropriate for primary care settings where laboratory testing is unavailable. CURB-65 is one of the most widely used pneumonia severity scores globally due to its simplicity and robust validation.

ICD-10 Classification Code:J96

🏥Signs & Symptoms

The following clinical signs and symptoms are commonly assessed when evaluating Acute Respiratory Failure:

  • Confusion (new-onset)
  • BUN > 19 mg/dL (7 mmol/L)
  • Respiratory Rate ≥ 30/min
  • SBP < 90 or DBP ≤ 60 mmHg
  • Age ≥ 65 years
  • RASS Level

🔬Causes & Etiology

The CURB-65 score was developed by Lim et al. as part of the British Thoracic Society (BTS) collaborative study, published in Thorax in 2003. It was designed as a simplified and validated severity assessment tool for community-acquired pneumonia (CAP) that could be readily calculated at the bedside. The score is derived from the earlier CURB score and incorporates five binary variables, each contributing 1 point: new-onset confusion (C), blood urea nitrogen greater than 19 mg/dL or urea greater than 7 mmol/L (U), respiratory rate of 30 breaths per minute or greater (R), systolic blood pressure below 90 mmHg or diastolic blood pressure 60 mmHg or less (B), and age 65 years or older (65). The total score ranges from 0 to 5, and the score correlates with 30-day mortality in a stepwise fashion. The validation cohort included over 80,000 patients across multiple countries. The CURB-65 score is recommended by the British Thoracic Society and the National Institute for Health and Care Excellence (NICE) for severity assessment in CAP. A related score called CRB-65 excludes the urea measurement and is appropriate for primary care settings where laboratory testing is unavailable. CURB-65 is one of the most widely used pneumonia severity scores globally due to its simplicity and robust validation.

The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team of critical care physicians, nurses, and pharmacists at Virginia Commonwealth University, with the original validation study published by Sessler et al. in the American Journal of Respiratory and Critical Care Medicine in 2002. The scale emerged from a need for a standardized, reliable tool to assess level of sedation and agitation in critically ill patients, addressing limitations of earlier scales like the Ramsay Sedation Scale. RASS is a 10-level ordinal scale ranging from +4 (combative, posing immediate danger to staff) through 0 (alert and calm) to -5 (unarousable, no response to voice or physical stimulation). The scale has demonstrated excellent inter-rater reliability (weighted kappa > 0.90) across diverse ICU populations and nursing shifts, and it has been validated against other sedation measures and neurophysiologic monitoring. The Society of Critical Care Medicine's Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption (PADIS) in Adult ICU Patients, published in 2018, explicitly recommend RASS as the preferred sedation assessment tool in mechanically ventilated patients. RASS is also a prerequisite for delirium assessment using the Confusion Assessment Method for the ICU (CAM-ICU), as CAM-ICU cannot be performed in patients with RASS -4 or -5. The scale is now the most widely used sedation assessment instrument in ICUs globally, integrated into sedation protocols, daily interruption bundles, and quality improvement initiatives aimed at reducing oversedation, ventilator days, and ICU length of stay.

📊Clinical Assessment & Risk Scoring

Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Acute Respiratory Failure:

  • CURB-65 Score Calculator

    The CURB-65 score is a validated clinical prediction tool used to assess the severity of community-acquired pneumonia and guide decisions on whether to treat patients as outpatients or admit them to the hospital.

  • RASS Score Calculator

    The Richmond Agitation-Sedation Scale (RASS) is a validated 10-level scale used in ICU to assess the level of sedation and agitation in patients. It ranges from +4 (combative) to -5 (unarousable).

🧬Diagnostic Logic & Scoring Breakdown

The CURB-65 score is calculated by summing 1 point for each of five binary clinical variables present at the time of initial assessment. The "C" criterion (confusion) is defined as new-onset disorientation to person, place, or time, or a Mental Test Score of 8 or less — this reflects acute brain dysfunction due to infection, hypoxia, or metabolic derangement. The "U" criterion (urea) is met when blood urea nitrogen exceeds 19 mg/dL (equivalent to serum urea > 7 mmol/L or approximately 40 mg/dL of urea); azotemia in pneumonia reflects dehydration, renal hypoperfusion, or underlying chronic kidney disease. The "R" criterion (respiratory rate) is met when the respiratory rate is 30 breaths per minute or greater; tachypnea is a sensitive marker of respiratory distress and impending respiratory failure. The "B" criterion (blood pressure) is met when systolic blood pressure is below 90 mmHg or diastolic blood pressure is 60 mmHg or less; hypotension in pneumonia indicates possible sepsis with vasodilation or hypovolemia. The "65" criterion (age) is met when the patient is 65 years or older; age is an independent risk factor for mortality in pneumonia due to immunosenescence and reduced physiologic reserve. The total score ranges from 0 to 5. The 30-day mortality rate shows a clear stepwise increase: 0.6-2.7% for score 0-1, 6.8% for score 2, 14-17.5% for score 3, and 27.8% for scores 4-5. The score is used to guide site-of-care decisions: scores of 0-1 are suitable for outpatient management, score 2 may require short-stay hospital observation, and scores of 3-5 generally require inpatient admission with consideration for ICU for scores 4-5.

📢Clinical Significance & Implications

The CURB-65 score is formally recommended by the British Thoracic Society (BTS) guidelines for the management of community-acquired pneumonia in adults (updated 2009) and by the National Institute for Health and Care Excellence (NICE) guideline NG195 (2019) for assessing pneumonia severity and guiding antibiotic prescribing. The score serves as the primary severity assessment tool in the UK National Health Service and is widely used internationally. In clinical practice, CURB-65 helps clinicians make evidence-based decisions about: (1) site of care — whether to manage as an outpatient, short-stay observation, or inpatient; (2) antibiotic choice — oral vs. intravenous therapy; and (3) level of monitoring. A score of 0-1 identifies low-risk patients who can be safely treated at home with oral antibiotics, potentially reducing unnecessary hospital admissions. A score of 2 identifies patients who may benefit from a short period of hospital observation. Scores of 3-5 identify high-risk patients requiring inpatient care, with scores of 4-5 warranting ICU assessment. The BTS guidelines also recommend the CRB-65 version (which omits the urea measurement) for use in primary care settings. Despite its widespread use, CURB-65 is less sensitive than the PSI/PORT score for identifying low-risk patients who can be safely treated as outpatients. Additionally, CURB-65 may underestimate severity in younger patients (who do not score for age) and does not account for important comorbidities, hypoxia, or social factors that may influence admission decisions. Therefore, CURB-65 should be used alongside clinical judgment rather than as a standalone decision tool.

🛡️Prevention & Management

Evidence-based prevention and management strategies for Acute Respiratory Failure include:

  • Manage as outpatient with oral antibiotics and follow-up in 24-48 hours.
  • Consider short-stay admission or observation with oral or IV antibiotics and close monitoring.
  • Admit for inpatient management with IV antibiotics. Consider ICU admission if score ≥ 4. Obtain blood and sputum cultures and chest imaging.
  • CURB-65 guides antibiotic route selection: scores 0-1 may use oral antibiotics, score 2 may use oral or IV, and scores 3-5 typically require IV antibiotics. This helps preserve oral therapy for appropriate patients.
  • Reduce sedation if clinically appropriate, assess for oversedation, perform daily sedation interruption trial, and monitor for delirium with CAM-ICU.
  • Yes. RASS can be used in any patient requiring sedation assessment, including non-intubated ICU patients, post-operative patients, and delirium monitoring.

💡 Clinical Assessment Scenario Example

An 80-year-old woman with no significant past medical history presents to the emergency department with a five-day history of productive cough, fever, and progressive dyspnea. Her family reports that over the past 24 hours she has become increasingly confused and disoriented. On examination, her temperature is 39.1°C, heart rate is 110 bpm, blood pressure is 100/60 mmHg, and respiratory rate is 32 breaths per minute with oxygen saturation of 87% on room air. Chest auscultation reveals coarse crackles over the right base. Chest X-ray confirms a right lower lobe consolidation. Laboratory results show white blood cell count 18,000/µL, BUN 25 mg/dL, creatinine 1.1 mg/dL, and serum glucose 110 mg/dL. CURB-65 assessment: confusion present (C = 1 point), BUN 25 > 19 mg/dL (U = 1 point), respiratory rate 32 ≥ 30 (R = 1 point), blood pressure 100/60 — systolic is 100, which is not below 90, and diastolic is 60, which equals 60 (B = 0 points), age 80 ≥ 65 (65 = 1 point). Total CURB-65 = 4 out of 5, indicating high severity with an expected 30-day mortality of approximately 27.8%. Management recommendations: immediate hospital admission, intravenous antibiotics (co-amoxiclav or ceftriaxone plus azithromycin per local guidelines), blood and sputum cultures, oxygen therapy to maintain SpO₂ ≥ 92%, close monitoring of respiratory status, and strong consideration for ICU-level care given her age, confusion, tachypnea, and elevated BUN. Daily reassessment of CURB-65 is warranted to track response to therapy.

💊Common Medications & Interventions

The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Acute Respiratory Failure:

AmoxicillinPenicillin antibiotic
AzithromycinMacrolide antibiotic
CeftriaxoneCephalosporin (3rd generation)
PropofolSedative-hypnotic (GABA agonist)
DexmedetomidineAlpha-2 agonist (sedative/analgesic)
MidazolamBenzodiazepine (GABA agonist)

⚠️Clinical Assessment Pitfalls

  • Mistake: Using BUN instead of serum urea in mmol/L

    Correction: The "U" in CURB-65 refers to BUN > 19 mg/dL (which is equivalent to urea > 7 mmol/L or 40 mg/dL). Check your local lab units carefully.

  • Mistake: Ignoring age in patients under 65 with severe pneumonia

    Correction: While age ≥ 65 gives 1 point, younger patients can still have severe pneumonia requiring admission. Use clinical judgment alongside the score.

  • Mistake: Using CURB-65 for hospital-acquired pneumonia

    Correction: CURB-65 was validated for community-acquired pneumonia (CAP). Other scores (PSI/PORT, SMART-COP) may be more appropriate for hospital-acquired pneumonia.

  • Mistake: Using CRB-65 when CURB-65 laboratory data is available

    Correction: CRB-65 is designed for settings without lab access. When BUN is available, always calculate CURB-65 for better prognostic accuracy.

  • Mistake: Not considering hypoxia and oxygen saturation

    Correction: CURB-65 does not include oxygen saturation. A patient with low SpO₂ but low CURB-65 may still require admission for oxygen therapy. Always assess oxygenation separately.

  • Mistake: Scoring RASS without attempting stimulation

    Correction: If the patient is not alert, begin with verbal stimulation (call name, command). If no response, proceed to physical stimulation (shake shoulder, rub sternum).

  • Mistake: Confusing RASS with GCS

    Correction: RASS measures sedation/agitation level; GCS measures consciousness. They serve different purposes — RASS for sedation titration, GCS for neurological assessment.

  • Mistake: Not considering pain before sedation

    Correction: In agitated patients, assess and treat pain first (with CPOT or BPS scale) before increasing sedation. Analgesia-first approach reduces sedation needs.

  • Mistake: Attempting CAM-ICU when RASS is -4 or -5

    Correction: CAM-ICU delirium assessment requires RASS -3 or higher. If RASS is -4 or -5, reassess after reducing sedation depth before attempting delirium evaluation.

  • Mistake: Not reassessing RASS after changes in sedation or clinical status

    Correction: RASS should be reassessed within 15-30 minutes after any sedation adjustment and whenever clinical status changes. Prompt assessment prevents oversedation or under-sedation.

🚑When to Seek Medical Attention

This reference supports clinical assessment of Acute Respiratory Failure; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.

Frequently Asked Questions

Q: What is the difference between CURB-65 and CRB-65?

CRB-65 excludes the BUN lab test, making it a purely clinical score usable in primary care. CRB-65 is calculated from: Confusion, RR ≥ 30, BP < 90/60, Age ≥ 65.

Q: Can CURB-65 be used in elderly patients?

Yes, but be cautious as age ≥ 65 already gives 1 point. Elderly patients may have atypical presentations — the absence of confusion or tachypnea does not rule out severe pneumonia.

Q: What score requires ICU admission?

A CURB-65 score of 4-5 indicates severe pneumonia with high mortality (14-27.8%). ICU admission should be strongly considered for these patients.

Q: Does CURB-65 replace chest imaging?

No. Chest imaging (X-ray or CT) is essential for confirming pneumonia diagnosis. CURB-65 is a severity assessment tool used after diagnosis is established.

Q: How was CURB-65 validated?

CURB-65 was validated in over 80,000 patients in multiple international studies. It has been shown to correlate well with 30-day mortality across different healthcare settings.

Q: What is the role of CURB-65 in antibiotic stewardship?

CURB-65 guides antibiotic route selection: scores 0-1 may use oral antibiotics, score 2 may use oral or IV, and scores 3-5 typically require IV antibiotics. This helps preserve oral therapy for appropriate patients.

Q: How does CURB-65 compare to PSI for low-risk classification?

PSI identifies more low-risk patients as eligible for outpatient care than CURB-65 due to its higher sensitivity for mortality prediction in low-score ranges. However, CURB-65 is simpler to calculate.

Q: What is the target RASS score for most ICU patients?

For most mechanically ventilated patients, a target of RASS 0 to -1 is recommended by the PADIS guidelines. This provides comfortable light sedation while allowing neurological assessment.

Q: How is RASS different from the Ramsay Sedation Scale?

RASS has a wider range including agitation (+1 to +4), which the Ramsay scale (1-6, sedation only) does not include. RASS also has better inter-rater reliability.

Q: Should RASS be assessed before or after procedures?

RASS should be assessed consistently at the same time each day (usually during morning rounds), before and after sedation adjustments, and whenever clinical status changes.

Q: How does RASS relate to delirium assessment?

RASS is used as the first step in delirium assessment with CAM-ICU. If the patient is RASS -4 or -5 (deeply sedated/unarousable), CAM-ICU cannot be performed.

Q: Can RASS be used in non-intubated patients?

Yes. RASS can be used in any patient requiring sedation assessment, including non-intubated ICU patients, post-operative patients, and delirium monitoring.

Q: What is daily sedation interruption and how does RASS guide it?

Daily sedation interruption involves temporarily holding sedative infusions until the patient demonstrates awakening (RASS 0 to -1). It reduces mechanical ventilation duration and is guided by serial RASS assessments.

Q: How does RASS relate to CPOT pain assessment?

The PADIS guidelines recommend assessing pain first (with CPOT or BPS) before sedation. A patient with RASS +2 may be agitated due to pain — treating pain may normalize RASS without additional sedatives.

📚Evidence-Based References

[1]
Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377-382.PubMed (12728155)
[2]
Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):iii1-iii55.View Source
[3]
NICE Guideline NG195. Pneumonia (community-acquired): antimicrobial prescribing. 2019.View Source
[4]
Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-250.PubMed (8995086)
[5]
Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27-S72.PubMed (17278083)
[6]
Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the ATS and IDSA. Am J Respir Crit Care Med. 2019;200(7):e45-e67.PubMed (31573350)
[7]
Chalmers JD, Mandal P, Singanayagam A, et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med. 2011;37(9):1409-1420.PubMed (21720768)
[8]
Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002;166(10):1338-1344.PubMed (12421743)
[9]
Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult ICU Patients (PADIS). Crit Care Med. 2018;46(9):e825-e873.PubMed (30113379)
[10]
Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA. 2003;289(22):2983-2991.PubMed (12799407)
[11]
Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial). Lancet. 2008;371(9607):126-134.PubMed (18191684)
[12]
Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263-306.PubMed (23269131)
[13]
Ely EW, Inouye SK, Bernard GR, et al. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA. 2001;286(21):2703-2710.PubMed (11730446)
Call Us
WhatsApp